{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-037467","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.231636+00:00","generated_at":"2026-06-17T11:53:39.925919+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MaxCyte names Douglas Swirsky as CFO; salary $425K, option for 350K shares","bullets":["Douglas J. Swirsky appointed CFO and principal accounting officer, effective March 27, 2023.","He receives $425K base salary, 45% target bonus, and a nonqualified stock option for 350K shares at $4.11/share.","Option vests over 4 years: 25% after 12 months, then monthly over 36 months.","Ron Holtz, who served as interim CFO since April 2022, becomes EVP, Administration.","Swirsky previously CFO of AavantiBio and CEO of Rexahn and GenVec; chairman of Cellectar Biosciences."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-037467","json":"https://secwatch.observer/filing/0001104659-23-037467.json","markdown":"https://secwatch.observer/filing/0001104659-23-037467.md","text":"https://secwatch.observer/filing/0001104659-23-037467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000110465923037467/0001104659-23-037467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000110465923037467/tm2310656d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T11:53:39.925919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c7ed720ce4","claim":"Ron Holtz changed role as EVP, Administration at MAXCYTE, INC..","evidence_excerpt":"Ron Holtz, who had served as the Company’s interim Chief Financial Officer since April 15, 2022, will continue as the Company’s EVP, Administration.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000110465923037467/0001104659-23-037467-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"continued as"},{"label":"Role","value":"EVP, Administration"}],"fact_type":"executive_change"},{"claim_id":"e912804a16","claim":"Douglas J. Swirsky was appointed as Chief Financial Officer at MAXCYTE, INC..","evidence_excerpt":"On March 27, 2023, the Board of Directors (the “ Board ”) of MaxCyte, Inc. (the “ Company ”) appointed Douglas J. Swirsky as the Company’s Chief Financial Officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000110465923037467/0001104659-23-037467-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}